KINDSTAR GLOBAL (09960): Wuhan Kang Shengda to Acquire 40% Equity in Huaxi Kang Shengda for RMB 12.396 Million

Stock News
2025/11/25

KINDSTAR GLOBAL (09960) announced that Wuhan Kang Shengda (a Chinese integrated entity) successfully acquired a 40% equity stake in Huaxi Kang Shengda (another Chinese integrated entity) from Huaxi Health Technology through a public listing process on the Beijing Equity Exchange. On November 25, 2025, Wuhan Kang Shengda entered into an equity transfer agreement with Huaxi Health Technology, agreeing to purchase the 40% stake for RMB 12.396 million. Upon completion of the transaction, Huaxi Kang Shengda will become an indirectly wholly-owned subsidiary of the company.

After careful evaluation by the board of directors, the transaction is deemed to align with the overall interests of the company and its shareholders. Specifically: 1. As a core platform for the group’s "National Specialized Testing Network + Regional Central Laboratory" strategy in Southwest China, Huaxi Kang Shengda has developed into a regional high-end specialized testing service provider covering Sichuan, Chongqing, Yunnan, and Guizhou, with established capabilities and experience in areas such as early cancer screening and molecular diagnostics. Full ownership will enhance the group’s centralized management of Huaxi Kang Shengda’s operations and strategic direction, ensuring efficient and consistent execution of the group’s overall strategy in the Southwest region.

2. As a leading third-party medical laboratory (ICL) platform, Huaxi Kang Shengda will strongly support the group’s dual-track development strategy of "ICL + IVD," driving synergies where "ICL drives IVD product development, and IVD enhances ICL service upgrades."

3. The company will take full control over Huaxi Kang Shengda’s management appointments, performance evaluations, and resource allocation, improving execution efficiency for cross-regional projects such as joint regional testing centers and collaborations with primary healthcare institutions. Additionally, the company will further extend and deepen clinical and research collaborations with West China Hospital of Sichuan University, better integrating regional channels, technology, and medical resources to strengthen unified regional operations.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10